Inhibition of the PI3K/AKT/mTOR pathway (Fig. 1F) and inhibition of lactic acid, which is the final product of glycolysis (Fig. 1G), further validated that shikonin can inhibit RA-glycolysis in FLSs. The gene discussed is MTOR; the disease is rheumatoid arthritis.